SHAREHOLDERS’ EQUITY

12 Months Ended

Dec. 31, 2024

Equity [Abstract]

SHAREHOLDERS’ EQUITY

NOTE 10 - SHAREHOLDERS’ EQUITY

A. The rights of Ordinary Shares are as follows:

The Ordinary Shares confer upon the shareholders the right to receive notice to participate and vote in general meetings of shareholders of the Company, the right to receive dividends, if declared, and the right to participate in a distribution of the surplus of assets upon liquidation of the Company.

B. Issuance of shares, warrants, and options.

1. Registered Direct Offering

On December 11, 2023, the Company raised $4,500 in gross proceeds through a registered direct offering of its ADSs. The Company issued a total of 4,500,000 ADSs (135,000,000 Ordinary Shares) at $1.00 per ADS. After deducting closing costs and fees, the Company received net proceeds of approximately $4,046, net of issuance costs.

Foresight Autonomous Holdings Ltd.

Notes to the consolidated financial statements

(Dollars in thousands, except per share data)

2. Public Offering and Registered Direct Offering.

On January 22, 2021, the Company entered into a sales agreement, pursuant to which the Company can sell from time to time, ADSs in the aggregate amount of up to $60,000 (the “January 2021 Sales Agreement”). Sales under the January 2021 Sales Agreement were made by any method permitted by law that is deemed to be an “at the market” offering as defined in Rule 415 promulgated under the Securities Act. Under the January 2021 Sales Agreement, during 2023, the Company sold, through the sales agent, an aggregate of 59,950 ADSs (1,798,500 Ordinary Shares), at an average price of $2.775 per ADS, raising gross proceeds of approximately $166. After deducting closing costs and fees, the Company received net proceeds of approximately $135, net of issuance costs.

On June 14, 2024, the Company entered into a sales agreement, pursuant to which the Company can sell from time to time, ADSs in the aggregate amount of up to $1,130 (the “June 2024 Sales Agreement”). Sales under the June 2024 Sales Agreement were made by any method permitted by law that is deemed to be an “at the market” offering as defined in Rule 415 promulgated under the Securities Act. Under the June 2024 Sales Agreement, in 2024 the Company sold, through the sales agent, an aggregate of 1,499,130 ADSs (44,973,900 Ordinary Shares), at an average price of $0.7 per ADS, raising gross proceeds of approximately $1,043. After deducting closing costs and fees, the Company received net proceeds of approximately $903, net of issuance costs.

3. Shares and warrants to service providers:

(a) Shares granted to service providers:

During 2022, the Company granted 320,000 Ordinary Shares to several service providers. The Company recorded in its 2022 statement of comprehensive loss an expense of $68 in respect of such grant included in general and administrative expenses.

During 2023 and 2024, the Company did not issue shares to service providers.

(b) Warrants, options and RSUs granted to service providers:

The fair value for the options granted to service providers during 2024 was estimated on the measurement date using a Black-Scholes option pricing model, with the following weighted-average assumptions: weighted average volatility of 88.99%, risk free interest rates of 3.8%, dividend yields of 0% and a weighted average life of the options of 4.26 years.

Between 2022 and 2024, the Company recorded share-based payments related to options granted to Magna’s employees and service providers of $149, $135, and 12, respectively, all included in research and development expenses in the statements of comprehensive loss. Additionally, in 2022, the Company recorded an expense of $8 due to the extension of the expiration dates for all options granted to Magna’s employees from three to seven years after the grant date.

On July 27, 2023, the Company’s shareholders approved a reduction to the exercise price of previously granted options to Magna’s employees to an exercise price of NIS 0.5 (approximately $0.13 per share at the approval date). The reduction was accounted for as a modification and as a result, the Company recorded an expense of $16 in its 2023 statement of comprehensive loss.

On August 8, 2024, the Company granted options to a service provider to purchase a total of 100,000 Ordinary Shares at an exercise price of NIS 0.5 (approximately $0.13 per share at the grant date) The options vest equally over twelve quarters until fully vested on July 1, 2027. The Company recorded an expense of $1 in its 2024 statement of comprehensive loss.

Foresight Autonomous Holdings Ltd.

Notes to the consolidated financial statements

(Dollars in thousands, except per share data)

On November 27, 2024, under the 2024 Share Incentive Plan, the Company granted 900,000 RSU’s (30,000 ADS’s) to a service provider. The RSU’s vest equally over eight quarters until fully vested on October 1, 2026. The Company recorded an expense of $3 in its 2024 statement of comprehensive loss.

4. Shares and options to employees

(a) Incentive Plans

In November 2015, the Board of Directors of the Company authorized a share option plan (“2016 Equity Incentive Plan”). The 2016 Equity Incentive Plan provides for the grant of share options to service providers, employees, and office holders of the Company. Awards may be granted under the 2016 Equity Incentive Plan until November 2025, when the 2016 Equity Incentive Plan expires.

According to the 2016 Equity Incentive Plan, the aggregate number of Ordinary Shares that may be granted pursuant to awards will not exceed 15% of the Company’s capital on a fully diluted basis.

On May 27, 2024, the Board of Directors of the Company authorized a share incentive plan (“2024 Share Incentive Plan”). The 2024 Share Incentive Plan also provides for the grant of Restricted Share Units (RSU’s) to service providers, employees, and office holders of the Company. Awards may be granted under the 2024 Share Incentive Plan until May 2034, when the 2024 Share Incentive Plan expires.

According to the 2024 Share Incentive Plan, the aggregate number of Ordinary Shares that may be granted pursuant to awards will not exceed 18% of the Company’s capital on a fully diluted basis

(b) 1. The fair value of options granted was estimated using the Black-Scholes option pricing model, and based on the following assumptions:

	As of December 31,	As of December 31,
	2023	2022
Exercise price	$0.8-$0.14	$0.28-$0.65
Expected volatility	95%-90%	93%-95%
Risk-free interest	4.5%-3.8%	1.5%-4.5%
Expected life of up to (years)	4.1-4.4	3.5-4.5

No stock options were granted to employees during the year ended December 31, 2024.

The weighted-average grant-date fair value of options granted during the years 2023, and 2022 was $0.04 and $0.09, respectively

2. The fair value of RSUs granted is determined based on the share price on the grant date

Foresight Autonomous Holdings Ltd.

Notes to the consolidated financial statements

(Dollars in thousands, except per share data)

The following table summarizes the option activity for the years ended December 31, 2024, 2023 and 2022 for options granted to employees, officers, and directors:

	As of December 31,
	2024							2023							2022
	Number of options			Weighted average exercise price		Weighted average remaining contractual term. (In years)		Number of options			Weighted average exercise price		Weighted average remaining contractual term. (In years)		Number of options			Weighted average exercise price		Weighted average remaining contractual term. (In years)
Outstanding at beginning of period		35,619,883		$	0.13		4.13		34,253,216		$	0.43		5.92		22,860,713		$	0.5		4.84
Granted		-							2,675,000							13,075,000
Exercised		-							-							(33,333	)
Forfeited		(4,971,112	)						(1,308,333	)						(1,649,164	)
Outstanding at the end of period		30,648,771		$	0.14		4.1		35,619,883		$	0.13		4.13		34,253,216		$	0.43		5.92
Exercisable at the end of period		25,321,689							23,525,726							19,427,796

As of December 31, 2024, the total unrecognized share-based payment expenses related to nonvested awards was $269, which is expected to be recognized over the next 2 years.

(c) Options granted during 2023 and 2022.

On May 23, 2022, the Company’s Board of Directors approved a reduction to the exercise price of previously granted options for 27 employees, under the Company’s 2016 Equity Incentive Plan, with an exercise price of NIS 2.29 to an exercise price of NIS 1. As a result, the Company recorded an expense of $20, $30 and $39, respectively, in its 2024 ,2023 and 2022 statement of comprehensive loss.

On August 18, 2022, the Company granted options to five of its senior officers to purchase an aggregate of 4,200,000 Ordinary Shares, at an exercise price of NIS 1 (approximately $0.31 per share at the grant date). The options vest over 12 quarters until fully vested, starting from January 1, 2023. As a result, the Company recorded an expense of $109 and $140, respectively, in its 2024 and 2023 statement of comprehensive loss.

On October 20, 2022, the Company’s shareholders approved grants of options to three members of the Company’s Board of Directors, to the Company’s Vice President of Human Resources and to the Company’s Chief Executive Officer to purchase 400,000 each, 600,000 and 4,000,000, respectively, of the Company’s Ordinary Shares at an exercise price of NIS 1 (approximately $0.28 per share at the grant date), which exercise price was thereafter reduced to NIS 0.5 (approximately $0.13 per share at the grant date). The options vest over 12 quarters until fully vested. The Company recorded an expense of $108, $108 and $6, respectively, in its 2024, 2023 and 2022 statement of comprehensive loss, included in general and administrative expenses.

Foresight Autonomous Holdings Ltd.

Notes to the consolidated financial statements

(Dollars in thousands, except per share data)

During 2022, the Company granted options to purchase 1,225,000 Ordinary Shares to its employees at an exercise price of NIS 2.29 (approximately $0.72 per share at the grant date), which exercise price was thereafter reduced to NIS 1 (approximately USD 0.27), and again reduced to NIS 0.5 (approximately USD 0.14), with some of the options vesting equally over twelve quarters, and some of the options having a one-year cliff and the remainder vesting equally over eight quarters. In addition, the Company granted options to purchase 75,000 Ordinary Shares to its employees at an exercise price of NIS 1.95 (approximately $0.61 per share at the grant date), which exercise price was thereafter reduced to NIS 0.5 (approximately USD 0.14), all the options vest on the grant date. Furthermore, the Company granted options to purchase 1,775,000 Ordinary Shares to its employees at an exercise price of NIS 1 (approximately USD 0.28 per share at the grant date, which exercise price was thereafter reduced to NIS 0.5 ( approximately USD 0.14), with some of the options vesting equally over twelve quarters, and some of the options having a one-year cliff and the remainder vesting equally over eight quarters. As a result, the Company recorded an expense of $60, $89 and $64, respectively, in its 2024, 2023 and 2022 statement of comprehensive loss.

On March 29, 2023, the Company granted options to purchase 375,000 Ordinary Shares to its employees at an exercise price of NIS 1 (approximately $0.28 per share at the grant date), with some of the options vesting equally over twelve quarters, and some of the options having a one-year cliff and the remainder vesting equally over eight quarters. The Company recorded an expense of $5 and $6, respectively, in its 2024 and 2023 statement of comprehensive loss included in research and development expenses.

On May 31, 2023, the Company’s Board of Directors approved a reduction to the exercise price of previously granted options for all outstanding options previously issued, under the Company’s 2016 Equity Incentive Plan, to an exercise price of NIS 0.5 (approximately $0.13 per share at the approval date). As a result, the Company recorded an expense of $47 and $211, respectively, in its 2024 and 2023 statement of comprehensive loss.

On July 27, 2023, the Company’s shareholders approved grants of options to two members of the Company’s Board of Directors, each to purchase 400,000 of the Company’s Ordinary Shares at an exercise price of NIS 0.5 (approximately $0.13 per share at the grant date). The options vest over 12 quarters until fully vested. The Company recorded an expense of $15 and $8, respectively, in its 2024 and 2023 statement of comprehensive loss, included in general and administrative expenses.

During 2023, the Company granted options to purchase 1,500,000 Ordinary Shares to its employees at an exercise price of NIS 0.5 (approximately $0.13 per share at the grant date), with 1,225,000 of the options vesting equally over twelve quarters, and 275,000 of the options having a one-year cliff and the remainder vesting equally over eight quarters. As a result, the Company recorded an expense of $12 and $3, respectively, in its 2024 and 2023 statement of comprehensive loss.

(d) RSU’s granted During 2024:

On July 15, 2024, under the 2024 Share Incentive Plan, the Company granted a total of 54,975,000 RSUs to members of the Company’s Board of Directors, officers and employees, with a fair value of $0.04 per RSU at the grant date. During 2024, 3,958,740 RSUs were exercised, and 6,217,500 RSUs were forfeited. The RSUs vest over 36 months, one-third vest after one year and the balance of the RSU vest over eight quarters until fully vested. Some RSUs vest equally over twelve quarters. The Company recorded an expense of $289 in respect of such grants in its 2024 statement of comprehensive loss.

On November 27, 2024, the Company granted 1,740,000 RSUs to employees. The RSUs vest over 36 months, with one-third vesting after one year and the remaining RSUs vesting over the following eight quarters. Some RSUs vest equally over twelve quarters. Since the vesting period begins on January 1, 2025, no expenses were recorded in the 2024 statement of comprehensive income.

(e) Options granted to Eye-Net’s employees.

Eye-Net grants its employee’s options to purchase its own shares. Utilizing parameters for calculating Black-Scholes similar to those of Foresight, with the only difference being in the share price and exercise price.

On August 19, 2020, the Company’s subsidiary, Eye-Net, granted options to purchase 8,700 ordinary shares of Eye-Net to its employees at an exercise price of $100 per share. The options vest over 12 quarters until fully vested on June 30, 2023. The Company recorded an expense of $57, and $115, respectively, in respect of such grant, in its 2023 and 2022 statement of comprehensive loss.

Foresight Autonomous Holdings Ltd.

Notes to the consolidated financial statements

(Dollars in thousands, except per share data)

During 2021, the Company’s subsidiary, Eye-Net, granted options to purchase 4,850 ordinary shares of Eye-Net to its employees at an exercise price of $100 per share. 4,500 options vests over 36 months, one third of the options vest after one year and the balance of the remaining options vest over eight quarters until fully vested. 350 options vests over 11 quarters until fully vested. The Company recorded an expense of $23, $51 and 96, respectively, in respect of such grant in its 2024, 2023 and 2022 statement of comprehensive loss.

During 2022, the Company’s subsidiary, Eye-Net, granted options to purchase 1,350 ordinary shares of Eye-Net to its employees. The options vest over 36 months, one third of the options vest after one year and the balance of the remaining options vest over eight quarters until fully vested .450 options were granted at an exercise price of $100 and 900 options were granted at an exercise price of $200 per share. The Company recorded an expense of $26, $28 and $14, respectively, in respect of such grant in its 2024, 2023 and 2022 statement of comprehensive loss.

During 2023, the Company’s subsidiary, Eye-Net, granted options to purchase 150 ordinary shares of Eye-Net to its employees. The options vest over 36 months, one third of the options vest after one year and the balance of the remaining options vest over eight quarters until fully vested. The options were granted at an exercise price of $200 per share. The Company recorded an expense of $4 and $4, respectively, in respect of such a grant in its 2024 and 2023 statement of comprehensive loss.

During 2024, the Company’s subsidiary, Eye-Net, granted options to purchase 1250 ordinary shares of Eye-Net to its employees. The options vests over 36 months, one third of the options vest after one year and the balance of the remaining options vest over eight quarters until fully vested. The options were granted at an exercise price of $200 per share. The Company recorded an expense of $7 in respect of such grant in its 2024 statement of comprehensive loss.

5. Share Based Compensation Expense:

The total share-based compensation expense, related to Ordinary Shares, RSUs, options granted to employees, directors and service providers was comprised, at each period, as follows:

	Year ended December 31,
	2024		2023		2022
	USD in thousands
Cost of revenues		1		9		25
Research and development		387		849		929
Sales and Marketing		36		118		196
General and administrative		364		465		676
		788		1,441		1,826
Less: Share-based compensation expense attributable to non-controlling interests		61		150		225
Share-based compensation expense attributable to Foresight Autonomous Holdings Ltd.		727		1,291		1,601